Cardiff Oncology, Inc. (CRDF)
CRDF Stock Price Chart
Explore Cardiff Oncology, Inc. interactive price chart. Choose custom timeframes to analyze CRDF price movements and trends.
CRDF Company Profile
Discover essential business fundamentals and corporate details for Cardiff Oncology, Inc. (CRDF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Jul 2004
Employees
31.00
Website
https://www.cardiffoncology.comCEO
Mani Mohindru
Description
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
CRDF Financial Timeline
Browse a chronological timeline of Cardiff Oncology, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.17, while revenue estimate is $62.78k.
Earnings released on 14 May 2026
EPS came in at -$0.18 falling short of the estimated -$0.13 by -38.46%, while revenue for the quarter reached $41.00k , missing expectations by -53.71%.
Earnings released on 24 Feb 2026
EPS came in at -$0.11 surpassing the estimated -$0.18 by +38.89%, while revenue for the quarter reached $243.00k , beating expectations by +134.78%.
Earnings released on 6 Nov 2025
EPS came in at -$0.17 surpassing the estimated -$0.20 by +15.00%, while revenue for the quarter reached $120.00k , beating expectations by +15.94%.
Earnings released on 29 Jul 2025
EPS came in at -$0.21 falling short of the estimated -$0.19 by -10.53%, while revenue for the quarter reached $121.00k , beating expectations by +10.63%.
Earnings released on 8 May 2025
EPS came in at -$0.20 falling short of the estimated -$0.19 by -5.26%, while revenue for the quarter reached $109.00k , beating expectations by +22.07%.
Earnings released on 27 Feb 2025
EPS came in at -$0.21 surpassing the estimated -$0.26 by +19.23%, while revenue for the quarter reached $151.00k , beating expectations by +60.35%.
Earnings released on 7 Nov 2024
EPS came in at -$0.25 surpassing the estimated -$0.27 by +7.41%, while revenue for the quarter reached $165.00k , beating expectations by +135.71%.
Earnings released on 8 Aug 2024
EPS came in at -$0.26 falling short of the estimated -$0.25 by -4.00%, while revenue for the quarter reached $163.00k , beating expectations by +171.67%.
Earnings released on 2 May 2024
EPS came in at -$0.22 surpassing the estimated -$0.25 by +12.00%, while revenue for the quarter reached $205.00k , beating expectations by +192.86%.
Earnings released on 29 Feb 2024
EPS came in at -$0.21 surpassing the estimated -$0.26 by +19.23%, while revenue for the quarter reached $156.00k , beating expectations by +290.00%.
Earnings released on 2 Nov 2023
EPS came in at -$0.22 surpassing the estimated -$0.29 by +24.14%, while revenue for the quarter reached $141.00k , beating expectations by +252.50%.
Earnings released on 9 Aug 2023
EPS came in at -$0.25 surpassing the estimated -$0.27 by +7.41%, while revenue for the quarter reached $108.00k , beating expectations by +170.00%.
Earnings released on 4 May 2023
EPS came in at -$0.25 falling short of the estimated -$0.23 by -8.70%, while revenue for the quarter reached $83.00k , beating expectations by +38.33%.
Earnings released on 2 Mar 2023
EPS came in at -$0.20 surpassing the estimated -$0.25 by +20.00%, while revenue for the quarter reached $128.00k , beating expectations by +74.74%.
Earnings released on 3 Nov 2022
EPS came in at -$0.20 surpassing the estimated -$0.27 by +25.93%, while revenue for the quarter reached $93.00k , beating expectations by +36.36%.
Earnings released on 4 Aug 2022
EPS came in at -$0.24 surpassing the estimated -$0.25 by +4.00%, while revenue for the quarter reached $91.00k , missing expectations by -2.15%.
Earnings released on 5 May 2022
EPS came in at -$0.25 falling short of the estimated -$0.23 by -8.70%, while revenue for the quarter reached $74.00k , beating expectations by +30.74%.
Earnings released on 24 Feb 2022
EPS came in at -$0.23 falling short of the estimated -$0.17 by -35.29%, while revenue for the quarter reached $133.00k , beating expectations by +224.39%.
Earnings released on 4 Nov 2021
EPS came in at -$0.17 matching the estimated -$0.17, while revenue for the quarter reached $86.00k , beating expectations by +186.67%.
Earnings released on 5 Aug 2021
EPS came in at -$0.17 falling short of the estimated -$0.15 by -13.33%, while revenue for the quarter reached $68.00k , missing expectations by -54.67%.
CRDF Stock Performance
Access detailed CRDF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
